Thomas M Kuczmarski1, Oreofe O Odejide2. 1. Department of Internal Medicine, Brigham and Women's Hospital, Boston, MA, USA. 2. Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA, 02215, USA. Oreofe_Odejide@dfci.harvard.edu.
Abstract
PURPOSE OF REVIEW: The medical field has a critical role not only in prolonging life but also in helping patients achieve a good death. Early studies assessing end-of-life quality indicators to capture if a good death occurred demonstrated low rates of hospice use and high rates of intensive healthcare utilization near death among patients with hematologic malignancies, raising concerns about the quality of death. In this review, we examine trends in end-of-life care for patients with hematologic malignancies to determine if we are close to the goal of a good death. RECENT FINDINGS: Several cohort studies show that patients with blood cancers are often inadequately prepared for the dying process due to late goals of care discussions and they experience low rates of palliative and hospice care. More recent analyses of population-based data demonstrate some improvements over time, with significantly more patients receiving palliative care, enrolling in hospice, and having the opportunity to die at home compared to a decade ago. These encouraging trends are paradoxically accompanied by concomitant increases in late hospice enrollment and intensive healthcare utilization near death. Although we are closer to the goal of a good death for patients with hematologic malignancies, there is ample room for growth. To close the gap between the current state of care and a good death, we need research that engages patients, caregivers, hematologic oncologists, and policy-makers to develop innovative interventions that improve timeliness of goals of care discussions, expand palliative care integration, and increase hospice use.
PURPOSE OF REVIEW: The medical field has a critical role not only in prolonging life but also in helping patients achieve a good death. Early studies assessing end-of-life quality indicators to capture if a good death occurred demonstrated low rates of hospice use and high rates of intensive healthcare utilization near death among patients with hematologic malignancies, raising concerns about the quality of death. In this review, we examine trends in end-of-life care for patients with hematologic malignancies to determine if we are close to the goal of a good death. RECENT FINDINGS: Several cohort studies show that patients with blood cancers are often inadequately prepared for the dying process due to late goals of care discussions and they experience low rates of palliative and hospice care. More recent analyses of population-based data demonstrate some improvements over time, with significantly more patients receiving palliative care, enrolling in hospice, and having the opportunity to die at home compared to a decade ago. These encouraging trends are paradoxically accompanied by concomitant increases in late hospice enrollment and intensive healthcare utilization near death. Although we are closer to the goal of a good death for patients with hematologic malignancies, there is ample room for growth. To close the gap between the current state of care and a good death, we need research that engages patients, caregivers, hematologic oncologists, and policy-makers to develop innovative interventions that improve timeliness of goals of care discussions, expand palliative care integration, and increase hospice use.
Entities:
Keywords:
End-of-life care; Goals of care discussions; Good death; Hematologic malignancies; Hospice; Palliative care
Authors: Sean A Fletcher; Angel M Cronin; Amer M Zeidan; Oreofe O Odejide; Steven D Gore; Amy J Davidoff; David P Steensma; Gregory A Abel Journal: Cancer Date: 2016-02-23 Impact factor: 6.860
Authors: Emily A Meier; Jarred V Gallegos; Lori P Montross Thomas; Colin A Depp; Scott A Irwin; Dilip V Jeste Journal: Am J Geriatr Psychiatry Date: 2016-01-22 Impact factor: 4.105
Authors: Winnie S Wang; Joseph D Ma; Sandahl H Nelson; Carolyn Revta; Gary T Buckholz; Carolyn M Mulroney; Eric J Roeland Journal: J Oncol Pract Date: 2017-06-23 Impact factor: 3.840
Authors: Areej El-Jawahri; Thomas W LeBlanc; Linda J Burns; Ellen Denzen; Christa Meyer; Lih-Wen Mau; Eric J Roeland; William A Wood; Effie Petersdorf Journal: Cancer Date: 2018-10-05 Impact factor: 6.860
Authors: Apar Kishor Ganti; Stephanie J Lee; Julie M Vose; Marcel P Devetten; R Gregory Bociek; James O Armitage; Philip J Bierman; Lori J Maness; Elizabeth C Reed; Fausto R Loberiza Journal: J Clin Oncol Date: 2007-12-10 Impact factor: 44.544
Authors: Kathy J Selvaggi; Judith B Vick; Susan A Jessell; John Lister; Janet L Abrahm; Rachelle Bernacki Journal: J Community Support Oncol Date: 2014-02
Authors: Vinay B Rao; Emmanuelle Belanger; Pamela C Egan; Thomas W LeBlanc; Adam J Olszewski Journal: J Palliat Med Date: 2020-06-29 Impact factor: 2.947
Authors: Dorothy McCaughan; Eve Roman; Alexandra G Smith; Anne C Garry; Miriam J Johnson; Russell D Patmore; Martin R Howard; Debra A Howell Journal: BMC Palliat Care Date: 2018-02-21 Impact factor: 3.234
Authors: Dorothy McCaughan; Eve Roman; Alexandra G Smith; Anne Garry; Miriam Johnson; Russell Patmore; Martin Howard; Debra A Howell Journal: BMJ Support Palliat Care Date: 2017-06-29 Impact factor: 3.568